title: Rationale and design of a trial on the effect of angiotensin II receptor blockers on the function of the systemic right ventricle.
abstract: BACKGROUND
  Angiotensin II receptor blockers have been proven to be beneficial in left ventricular failure. In patients with a morphologic right ventricle supporting the systemic circulation, its efficacy has not yet been established.
  
  
  METHODS
  We designed a multicenter, prospective, randomized, double-blind, placebo-controlled trial studying the effect of valsartan in patients with a systemic right ventricle due to a congenitally or surgically corrected transposition of the great arteries. The primary end point is the change in right ventricular ejection fraction as measured by cardiovascular magnetic resonance or multidetector row cardiac computed tomography in case of pacemaker patients.
  
  
  CONCLUSIONS
  This large prospective, double-blind, randomized, placebo-controlled trial will establish the role of angiotensin II receptor blockers (valsartan) in the treatment of patients with a systemic right ventricle.
authors.affiliation: Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands. b.j.mulder@amc.uva.nl
authors.forename: Teun
authors.initials: T
authors.lastname: van der Bom
authors.forename: Michiel M
authors.initials: MM
authors.lastname: Winter
authors.forename: Berto J
authors.initials: BJ
authors.lastname: Bouma
authors.forename: Maarten
authors.initials: M
authors.lastname: Groenink
authors.forename: Hubert W
authors.initials: HW
authors.lastname: Vliegen
authors.forename: Petronella G
authors.initials: PG
authors.lastname: Pieper
authors.forename: Arie P J
authors.initials: AP
authors.lastname: van Dijk
authors.forename: Gertjan T
authors.initials: GT
authors.lastname: Sieswerda
authors.forename: Jolien W
authors.initials: JW
authors.lastname: Roos-Hesslink
authors.forename: Aielko H
authors.initials: AH
authors.lastname: Zwinderman
authors.forename: Barbara J M
authors.initials: BJ
authors.lastname: Mulder
mesh_terms: D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006325:Heart Atria / Q000002:abnormalities* / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D011446:Prospective Studies; D013318:Stroke Volume / Q000187:drug effects*; D013777:Tetrazoles / Q000008:administration & dosage*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014633:Valine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000068756:Valsartan; D018497:Ventricular Dysfunction, Right / Q000151:congenital / Q000188:drug therapy* / Q000503:physiopathology; D016278:Ventricular Function, Right / Q000187:drug effects*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D013777:Tetrazoles; D000068756:Valsartan; D014633:Valine